Clinical trials: Colon Adenocarcinoma
Melanoma, Non-small Cell Lung Cancer
A Study of IBI363 in Subjects with Advanced Solid Malignancies
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
- Trial name
- NCT06281678
- Testing
- IBI363
- Where
- 9 sites in United States
- Volunteers
- 178 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05983133
- Testing
- PF-08046052
- Where
- 24 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Esophagus Cancer, Stomach Cancer
Effects of S-1 and Capecitabine on Coronary Artery Blood Flow
Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are occasionally associated with cardiac toxicity.
- Conditions
- Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer
- Trial name
- FluoHeart (NCT02216149)
- Testing
- S-1, Capecitabine, Oxaliplatin
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Heikki Joensuu
Colorectal Cancer
GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer
RATIONALE: Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy or kill tumor…
- Trial name
- NCT00262808
- Testing
- sargramostim, fluorouracil, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Rochester
Breast Cancer, Head and Neck Squamous Cell Carcinoma
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer.
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT03195699
- Testing
- TTI-101
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Colorectal Cancer
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00496704
- Testing
- capecitabine, gemcitabine hydrochloride, oxaliplatin
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yonsei University
Recurrent Colon Cancer, Recurrent Rectal Cancer
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT01294826
- Testing
- AUY922, Cetuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Colorectal Carcinoma, Gastric Adenocarcinoma
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX).
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04430738
- Testing
- tucatinib, trastuzumab, oxaliplatin
- Where
- 27 sites in United States, Japan
- Volunteers
- 40 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Hepatocellular Carcinoma, Cholangiocarcinoma
Observational Study on Patients With Hepatobiliary Tumors
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Gallbladder Cancer, Biliary Tract Cancer
- Trial name
- NCT04637048
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Gang Chen, MD
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC)
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants…
- Conditions
- Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
- Trial name
- ALAFOSS-01 (NCT06599502)
- Testing
- AZD0022, Cetuximab
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Adenocarcinoma, Colon Cancer
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.
- Trial name
- NCT00127036
- Testing
- XELOX, XELIRI, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
The purpose of this study is to establish the safety of Zaltrap in patients who undergo pre-operative chemotherapy with Zaltrap. The investigators hypothesize that Zaltrap my impact colorectal cancer growth and metastasis.
- Trial name
- NCT02046538
- Testing
- Leucovorin, Oxaliplatin, 5-FU
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to…
- Trial name
- NCT01040000
- Testing
- NPC-1C/NEO-102
- Where
- 6 sites in United States
- Volunteers
- 94 people
- Sponsor
- Precision Biologics, Inc
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Solid Tumor, Hepatocellular Carcinoma
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, Glioma
- Trial name
- NCT04550663
- Testing
- KD-025 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Colorectal Cancer, Liver Metastasis
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Background: Some types of inflammation may increase the risk of cancers in the intestinal track. Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and spread.
- Conditions
- Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
- Trial name
- NCT01856322
- Testing
- Sulindac, Validate assays and shipping methods
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
HER2-Expressing Solid Tumors
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors.
- Trial name
- NCT07334119
- Testing
- MT-304, MT-304 + Nivolumab
- Where
- 7 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Myeloid Therapeutics